Objective: Some patients with schizophrenia may need mirtazapine augmentation to improve negative and cognitive symptoms. However there have been a few studies about the tolerability of mirtazapine augmentation to antipsychotics such as akathisia, extrapyramydal symptoms, weight gain, and body mass index (BMI).
Methods: This study was an eight-week double-blind, randomized controlled trial (RCT) of mirtazapine augmentation to risperidone. Twenty-one stabilized participants diagnosed with schizophrenia and undergoing treatment with risperidone were randomized to adjunctive treatment with mirtazapine (15 mg/day for the first two weeks, 30 mg/day for the next six weeks) or placebo. Eleven patients were assigned to the mirtazapine group, and nine patients were given placebo.
Results: There was no significant difference between the mirtazapine and placebo groups with respect to Barnes Akathisia rating Scale (BAS) and Sympsom-Angus Scale (SAS). However, the mirtazapine group exhibited a statistically significant increase in weight and BMI (p<0.05).
Conclusion: These results suggest that mirtazapine augmentation can be tolerable in schizophrenic patients treated with risperidone; however, we should pay attention to the weight gain with mirtazapine. Our results should be replicated in a large-scale lengthy trial.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569079 | PMC |
| http://dx.doi.org/10.9758/cpn.2011.9.2.73 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"It's been a long time since I drank like that": A case report of binge drinking associated with aripiprazole.
Ment Health Clin
June 2024
Clinical Pharmacist Practitioner and Clinical Pharmacy Program Manager, Veterans Integrated Services Network 23 Clinical Resource Hub, Minneapolis, Minnesota.
Aripiprazole has been linked to the development of impulse control problems (ICPs), most commonly gambling. Aripiprazole's effect on serotonergic and dopaminergic pathways has had mixed results on drinking behaviors. A male patient receiving outpatient psychiatric care presented with ongoing symptoms of depression on his current regimen of mirtazapine and gabapentin.
View Article and Find Full Text PDFAntidepressant nonadherence and sexual dysfunction among young adult males: the cross-sectional YAMAN study.
World J Urol
May 2024
The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Article Synopsis
- Selective serotonin reuptake inhibitors (SSRIs) are linked to issues like high nonadherence rates and sexual dysfunction, particularly among young adult men, but the exact relationship is not well understood.
- A study surveyed 505 young men about their willingness to adhere to antidepressant treatment, revealing they preferred alternatives that spare sexual function, such as bupropion and mirtazapine, over SSRIs.
- Findings suggest that sexual side effects significantly influence the likelihood of young men not sticking to their antidepressant regimen, highlighting the need for better treatment strategies that include options to minimize these side effects.
Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials.
Clin Psychopharmacol Neurosci
May 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/ non-responders to clozapine.
View Article and Find Full Text PDFThe effective perospirone augmentation with clonazepam for treatment-resistant burning mouth syndrome: A case report.
Neuropsychopharmacol Rep
June 2024
Department of Psychosomatic Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Burning mouth syndrome (BMS) is characterized by burning sensations in the oral region without corresponding abnormalities and is often accompanied by uncomfortable sensations. Herein, we present cases of BMS in which the remaining uncomfortable sensations improved with perospirone augmentation with clonazepam. Case 1: A 61-year-old man complained of a burning pain in his tongue, a sensation of dryness and discomfort as if his tongue was sticking to a palatal plate.
View Article and Find Full Text PDF[Treatment resistance in anxiety disorders-Definition and treatment options].
Nervenarzt
May 2024
Fachbereich Psychosomatische Medizin, Kompetenzschwerpunkt Angst, kbo-Inn-Salzach-Klinikum, Wasserburg am Inn, Deutschland.
Treatment resistance in anxiety disorders represents a clinical challenge, contributes to the chronicity of the diseases as well as sequential comorbidities, and is associated with a significant individual and socioeconomic burden. This narrative review presents the operational definition of treatment resistance in anxiety disorders according to international consensus criteria (< 50% reduction in the Hamilton Anxiety Scale, HAM‑A, score or < 50% reduction in the Beck Anxiety Inventory, BAI, score or a clinical global impression-improvement, CGI‑I, score > 2). At least two unsuccessful guideline-based treatment attempts with pharmacological monotherapy or at least one unsuccessful treatment attempt with adequately delivered cognitive behavioral therapy are required.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!